Table 1.
Glycosylation status of HDL-associated proteins with confirmed glycosylation sites.
| Protein | N-glycans | O-glycans | Sites of attachment |
|---|---|---|---|
| Alpha-1-antichymotrypsin (AACT) | 8 | 0 | Asn106, Asn127, Asn271 |
| Alpha-1-antitrypsin (A1AT) | 18 | 0 | Asn70, Asn107, Asn271 |
| Alpha-1B-glycoprotein (A1BG) | 1 | 0 | Asn179 |
| Alpha-2-HS-glycoprotein (FETUA or A2HSG) | 17 | 2 | Asn156, Asn176, Thr346 |
| Apolipoprotein A-II (APOA2) | 0 | 4 | Ser35, Ser88, Thr95 |
| Apolipoprotein C-III (APOC3) | 0 | 21 | Thr94 |
| Apolipoprotein D (APOD) | 28 | 0 | Asn65, Asn98 |
| Apolipoprotein E (APOE) | 0 | 40 | Ser215, Thr307/Ser308*, Ser76/Thr83*, Ser129/Thr130*, Thr194, Ser197, Ser263, Thr289/Ser290* Ser296 (25, 41) |
| Apolipoprotein F (APOF) | 0 | 3 | Ser269, Thr273/Thr27* |
| Apolipoprotein M (APOM) | 9 | 0 | Asn135 |
| Clusterin (CLUS or APOJ) | 10 | 0 | Asn86, Asn291, Asn374 |
| Complement C1s subcomponent (C1S) | 2 | 0 | Asn174 |
| Complement C3 (C3) | 4 | 0 | Asn85 |
| Hemopexin (HPX) | 6 | 0 | Asn187, Asn453, Asn240/Asn246* |
| Heparin cofactor 2 (HCF2) | 2 | 0 | Asn49 |
| Kininogen-1 (KNG1) | 4 | 0 | Asn169, Asn205 |
| Lecithin-cholesterol acyltransferase (LCAT) | 1 | 0 | Asn108 |
| Serum amyloid A-4 (SAA4) | 7 | 0 | Asn94 |
| Serum paraoxonase/arylesterase 1 (PON1) | 8 | 0 | Asn253, Asn324 |
Proteins included in this table include only those with glycosylation sites confirmed to actually express glycans at those sites by mass spectrometry analysis of isolated HDL fractions from a starting volume of 500 uL of plasma, as described in (25). HDL-associated proteins that have been reported to be glycosylated previously, and/or have putative sites but that either could not be confirmed by mass spectrometry or are present at low abundance such that they fall under the limit of detection, are not reported in this table.
*For these sites, the site of attachment could not be disambiguated thus both possible attachment sites are reported.